Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Alings

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
American Heart Journal|March 8, 2017
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialB Daan Westenbrink, Marco Alings, Christopher B Granger, et al.
European Journal of Preventive Cardiology|October 17, 2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
European Heart Journal|February 6, 2018
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trialMichiel Rienstra, Anne H Hobbelt, Marco Alings, et al.
JAMA Network Open|September 16, 2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY TrialsZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Annals of Cardiothoracic Surgery|February 12, 2014
Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) IIIRichard Whitlock, Jeff Healey, Jessica Vincent, et al.
Psychosomatic Medicine|September 30, 2014
E-health to manage distress in patients with an implantable cardioverter-defibrillator: primary results of the WEBCARE trialMirela Habibović, Johan Denollet, Pim Cuijpers, et al.
Journal of Clinical Epidemiology|November 28, 2020
Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation studyWouter B van Dijk, Aernoud T L Fiolet, Ewoud Schuit, et al.
Journal of the American College of Cardiology|October 15, 2011
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) studyHessel F Groenveld, Harry J G M Crijns, Maarten P Van den Berg, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 30, 2021
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
Circulation|September 4, 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA TrialWilliam F McIntyre, Alexander P Benz, Jeff S Healey, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
American Heart Journal|March 8, 2017
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialB Daan Westenbrink, Marco Alings, Christopher B Granger, et al.
European Journal of Preventive Cardiology|October 17, 2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
European Heart Journal|February 6, 2018
Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trialMichiel Rienstra, Anne H Hobbelt, Marco Alings, et al.
JAMA Network Open|September 16, 2020
Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY TrialsZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Annals of Cardiothoracic Surgery|February 12, 2014
Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) IIIRichard Whitlock, Jeff Healey, Jessica Vincent, et al.
Psychosomatic Medicine|September 30, 2014
E-health to manage distress in patients with an implantable cardioverter-defibrillator: primary results of the WEBCARE trialMirela Habibović, Johan Denollet, Pim Cuijpers, et al.
Journal of Clinical Epidemiology|November 28, 2020
Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation studyWouter B van Dijk, Aernoud T L Fiolet, Ewoud Schuit, et al.
Journal of the American College of Cardiology|October 15, 2011
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) studyHessel F Groenveld, Harry J G M Crijns, Maarten P Van den Berg, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 30, 2021
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
Circulation|September 4, 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA TrialWilliam F McIntyre, Alexander P Benz, Jeff S Healey, et al.
Pageof 13